The effect of oral dexamethasone on duration of analgesia after upper limb surgery under infraclavicular brachial plexus block: a randomised controlled trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 204 KB, PDF-dokument
The effects of oral dexamethasone on peripheral nerve blocks have not been investigated. We randomly allocated adults scheduled for forearm or hand surgery to oral placebo (n = 61), dexamethasone 12 mg (n = 61) or dexamethasone 24 mg (n = 57) about 45 min before lateral infraclavicular block. Mean (SD) time until first pain after block were: 841 (327) min; 1171 (318) min; and 1256 (395) min, respectively. Mean (98.3%CI) differences in time until first postoperative pain for dexamethasone 24 mg vs. placebo and vs. dexamethasone 12 mg were: 412 (248–577) min, p < 0.001; and 85 (-78 to 249) min, p = 0.21, respectively. Mean (98.3%CI) difference in time until first postoperative pain for dexamethasone 12 mg vs. placebo was 330 (186–474) min, p < 0.001. Both 24 mg and 12 mg of oral dexamethasone increased the time until first postoperative pain compared with placebo in patients having upper limb surgery under infraclavicular brachial plexus block.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Anaesthesia |
| Vol/bind | 78 |
| Udgave nummer | 12 |
| Sider (fra-til) | 1465-1471 |
| Antal sider | 7 |
| ISSN | 0003-2409 |
| DOI | |
| Status | Udgivet - 2023 |
| Eksternt udgivet | Ja |
Bibliografisk note
Funding Information:
This trial was prospectively registered on ClinicalTrials.gov (NCT04853446) and in the European Clinical Trials Database (EudraCT 2021‐000428‐36). This trial was funded by the Region of Zealand Research Fund. Data will be made available upon reasonable request to the corresponding author. TL has been chair at the Nordic advisory board meeting concerning remimazolam for Paion Scandic. The Department of Anaesthesiology, Zealand University Hospital, Køge, has conducted contract research for AM‐Pharma and has received funding from the Novo Nordisk Foundation, Independent Research Fund Denmark, and Sygesikringen Danmark unrelated to the present work. We thank all the staff at the participating sites for their help with the trial. We thank Glostrup Pharmacy for preparing the trial medication, Janus Engstrøm (Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital – Rigshospitalet) for generating the allocation sequences. No other competing interests declared.
Funding Information:
This trial was prospectively registered on ClinicalTrials.gov (NCT04853446) and in the European Clinical Trials Database (EudraCT 2021-000428-36). This trial was funded by the Region of Zealand Research Fund. Data will be made available upon reasonable request to the corresponding author. TL has been chair at the Nordic advisory board meeting concerning remimazolam for Paion Scandic. The Department of Anaesthesiology, Zealand University Hospital, Køge, has conducted contract research for AM-Pharma and has received funding from the Novo Nordisk Foundation, Independent Research Fund Denmark, and Sygesikringen Danmark unrelated to the present work. We thank all the staff at the participating sites for their help with the trial. We thank Glostrup Pharmacy for preparing the trial medication, Janus Engstrøm (Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital – Rigshospitalet) for generating the allocation sequences. No other competing interests declared.
Publisher Copyright:
© 2023 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists.
ID: 390175804